Holen Sie sich die Stockscreener-App
12.97
0.61%
-0.08
Handel nachbörslich:
13.14
0.17
+1.31%
Schlusskurs vom Vortag:
$13.05
Offen:
$13.25
24-Stunden-Volumen:
247.88K
Relative Volume:
0.85
Marktkapitalisierung:
$176.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.17M
KGV:
-1.7374
EPS:
-7.465
Netto-Cashflow:
$-85.97M
1W Leistung:
+11.81%
1M Leistung:
+47.37%
6M Leistung:
+85.02%
1J Leistung:
+41.35%
1-Tages-Spanne:
$12.65
$13.70
1-Wochen-Bereich:
$10.87
$13.80
52-Wochen-Spanne:
$5.062
$15.10
Immunic Inc Stock (IMUX) Company Profile
Firmenname
Immunic Inc
Sektor
Branche
Telefon
(332) 255-9818
Adresse
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
12.97 | 177.76M | 0 | -97.17M | -85.97M | -7.465 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-17 | Eingeleitet | Stifel | Buy |
| 2026-04-15 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2026-03-24 | Eingeleitet | Guggenheim | Buy |
| 2025-11-07 | Eingeleitet | Roth Capital | Buy |
| 2025-09-29 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-25 | Eingeleitet | William Blair | Outperform |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-27 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-04-15 | Eingeleitet | Aegis Capital | Buy |
| 2021-03-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-10-02 | Eingeleitet | SVB Leerink | Outperform |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-07 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-06-05 | Eingeleitet | Wedbush | Outperform |
| 2020-05-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-11 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Immunic Inc Aktie (IMUX) Neueste Nachrichten
Wolfe Research initiated coverage on Immunic - Quantisnow
IMUX Maintained by B. Riley Securities -- Price Target Lowered t - GuruFocus
Immunic (IMUX) Price Target Reduced by B. Riley Analyst - GuruFocus
B. Riley Securities Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $27 - Moomoo
B. Riley Adjusts Price Target on Immunic to $27 From $40, Maintains Buy Rating - Moomoo
Wolfe Research initiates Immunic stock with outperform rating - Investing.com
Wolfe Research initiates Immunic stock with outperform rating By Investing.com - Investing.com Canada
Immunic Appoints New Chair of Board - Intellectia AI
IMMUNIC (IMUX) director Michael W. Bonney listed as insider in Form 3 filing - Stock Titan
Immunic Appoints Michael W. Bonney as Board Chair to Guide Late-Stage MS Therapy Development and Commercialization - Minichart
Immunic names Michael Bonney as board chair By Investing.com - Investing.com South Africa
Immunic appoints Michael Bonney as chairman - The Pharma Letter
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout - Yahoo Finance
Immunic Appoints New Chair of Board of Directors - Intellectia AI
Immunic Appoints Michael Bonney as Board Chair - TipRanks
Immunic Names Michael Bonney as Board Chair - Moomoo
Biotech veteran Michael Bonney becomes Immunic (NASDAQ: IMUX) chair - Stock Titan
Immunic names Michael Bonney as board chair - Investing.com
Immunic appoints seasoned biopharmaceutical executive Michael W. Bonney as chair of the board of directors - marketscreener.com
Press Release: Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors - Moomoo
Is Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Immunic stock (US45256V1061): Q1 loss widens as short interest collapses - AD HOC NEWS
Alyeska discloses 6.33M-share stake in Immunic (NASDAQ: IMUX) - Stock Titan
Immunic, Inc.Common Stock (NQ: IMUX - FinancialContent
Immunic announces 1-for-10 reverse stock split - MSN
A Quick Look at Today's Ratings for Immunic(IMUX.US), With a Forecast Between $19 to $56 - Moomoo
IMMUNIC (IMUX) amendment shows 683 Capital exit filing and 3.4% beneficial stake - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Immunic (IMUX), Tenon Medical, Inc. (TNON) - The Globe and Mail
Number of shareholders of Immunic, Inc. – NASDAQ:IMUX - TradingView
Roth MKM Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $19 - Moomoo
Number of shareholders of Immunic, Inc. – FWB:10V - TradingView
H.C. Wainwright reiterates Immunic stock rating citing trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Immunic stock rating citing trial progress - Investing.com UK
Immunic stock (US45256V1061): Q1 earnings and Phase 3 trial preparations - AD HOC NEWS
Immunic (IMUX) Q1 2026 Earnings: EPS N/A, Revenue N/A -- Is the - GuruFocus
Immunic Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Immunic (IMUX) Prepares for Pivotal Phase 3 Trials with Strength - GuruFocus
Immunic Releases Q1 2026 Financial Results - AlphaStreet
Immunic, Inc. Reports Q1 2026 Financial Results, Advances Phase 3 Trials for Vidofludimus Calcium in Multiple Sclerosis, and Raises $200M in Private Placement - Minichart
Immunic advances Phase 3 MS program, eyes topline data by year-end - Yahoo Finance
Immunic CEO on Q1 highlights, new appointments and upcoming milestones - Proactive financial news
Immunic, Inc. Q1 2026 Financial Results and Clinical Progress in Neurologic Disease Therapies - Minichart
IMUX: Vidofludimus calcium shows strong efficacy and safety in MS, targeting a $3-7B market - TradingView
Immunic reports Q1 2026 net loss $32.6M, cash $186.6M after $200M private placement - TradingView
IMMUNIC ($IMUX) Releases Q1 2026 Earnings - Quiver Quantitative
IMMUNIC, INC. 1Q 2026: Revenue $0 Net loss $32.6M — 10-Q Summary - TradingView
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Immunic (NASDAQ: IMUX) boosts cash with $200M warrant deal amid Q1 loss - Stock Titan
Immunic: Q1 Earnings Snapshot - marketscreener.com
Press Release: Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Finanzdaten der Immunic Inc-Aktie (IMUX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunic Inc-Aktie (IMUX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tardio Jason | President and COO |
Jun 05 '25 |
Buy |
0.79 |
12,512 |
9,884 |
12,512 |
| Vitt Daniel | CEO and Director |
Jun 04 '25 |
Buy |
0.77 |
15,000 |
11,550 |
29,000 |
| Neermann Joerg | Director |
Jun 04 '25 |
Buy |
0.77 |
70,000 |
53,900 |
170,000 |
| Neermann Joerg | Director |
Jun 05 '25 |
Buy |
0.76 |
30,000 |
22,800 |
200,000 |
| Whaley Glenn | Chief Financial Officer |
Jun 03 '25 |
Buy |
0.71 |
45,000 |
32,076 |
95,510 |
| Rudick Richard Alan | Director |
Jun 03 '25 |
Buy |
0.70 |
143,075 |
100,024 |
230,375 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):